Mesoblast's high-risk programs drive inflated valuation. Find out why MESO stock remains a "sell" as execution risks outweigh ...
Researchers from Cologne, Bochum, Padova and Angers have discovered a novel connection between mitochondrial function, ...
Four years after receiving Hemgenix in a Phase 3 trial, bleeding rates and the use of replacement therapy are low for men ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback